Biosergen AB Sustainability Reports
Biosergen AB is a clinical-stage biotechnology company focused on the development of novel anti-fungal therapeutics. Its lead drug candidate, BSG005, is designed to treat life-threatening invasive fungal infections in immunocompromised patients.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300YD2OGUE7BMP925
10 reports from 2021 to 2025
- Biosergen AB 2025 Annual Report with Consolidated Financial Statements
- Biosergen AB 2025 Annual Report and Consolidated Financial Statements
- Biosergen AB 2024 Annual Report and Consolidated Financial Statements
- Biosergen AB 2024 Annual Report and Consolidated Financial Statement
- Biosergen AB 2023 Annual Report and Consolidated Accounts
